The VITA Project: Population-based Distributions of Protein C, Antithrombin III, Heparin-cofactor II and Plasminogen -Relationship with Physiological Variables and Establishment of Reference Ranges

Francesco Rodeghiero; Alberto Tosetto

doi:10.1055/s-0038-1650559

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1996; 76(02): 226-233
DOI: 10.1055/s-0038-1650559

Original Article

Schattauer GmbH Stuttgart

The VITA Project: Population-based Distributions of Protein C, Antithrombin III, Heparin-cofactor II and Plasminogen -Relationship with Physiological Variables and Establishment of Reference Ranges

Francesco Rodeghiero

The Hemophilia and Thrombosis Center, Department of Hematology, S. Bortolo Hospital, Vicenza, Italy

,

Alberto Tosetto

The Hemophilia and Thrombosis Center, Department of Hematology, S. Bortolo Hospital, Vicenza, Italy

› Institutsangaben

Abstract

als PDF herunterladen

Summary

A proper laboratory diagnosis of inherited thrombophilia due to defects of the coagulation system may be obtained only by a stringent definition of the diagnostic reference ranges taking into account the influence exerted by major physiological variables. To this purpose, we analyzed the data for Protein C, Antithrombin III, Heparin-Cofactor II and plasminogen coming from the first 4,000 subjects enrolled in the VITA Project. This is the first study that allows the establishment of reference ranges in a non-selected, active population using stringent standardization of clinical and laboratory measurements and multivariable regression techniques for data analysis.

Serum triglycerides and total cholesterol, together with plasma fibrinogen were found to influence the functional plasma level of the four considered proteins. Menopause increased AT-III concentration, while pill use increased Heparin-Cofactor II and plasminogen. PT and PTT ratio, gender, age, smoking, body-mass index, HDL cholesterol and blood group had minor effects. The effect of these variables should be taken into account for both clinical and epidemiologic purposes, using appropriate reference ranges or covariance analysis for adjustment.

PDF (446 kb)

Referenzen

References
1 Mannucci PM, Tripodi A. Laboratory screening of inherited thrombotic syndromes. Thromb Haemost 1987; 57: 247-251
2 Tosetto A, Frezzato M, Rodeghiero F. Family history and inherited thrombophilia. Br J Haematol 1995; 89: 227-228
3 Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briet E. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993; 341: 134-138
4 Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG. Inherited predisposition to thrombosis. Cell 1993; 72: 477-480
5 Tait RC, Walker ID, Islam SIAM, McCall F, Conkie JA, Wight M, Mitchell R, Davidson JF. Protein C activity in healthy volunteers. Influence of age, sex, smoking and oral contraceptives. Thromb Haemost 1993; 70: 281-285
6 Tait RC, Walker ID, Islam SIAM, McCall F, Conkie JA, Mitchell R, Davidson JF. Influence of demographic factors on antithrombin III activity in a healthy population. Br J Haematol 1993; 84: 476-480
7 Tait RC, Walker ID, Conkie JA, Islam SIAM, McCall F, Mitchell R, Davidson JF. Plasminogen levels in healthy volunteers. Influence of age, sex, smoking and oral contraceptives. Thromb Haemost 1992; 68: 506-510
8 Dolan G, Neal K, Cooper P, Brown P, Preston FE. Protein C, antithrombin III and plasminogen: effect of age, sex and blood group. Br J Haematol 1994; 86: 798-803
9 Rodeghiero F, Tosetto A. Some remarks on the epidemiology of thrombotic disorders. Thromb Haemost 1993; 69: 527-528
10 Kleinbaum DG, Kupper LL, Muller KE. Applied regression analysis and other multivariable methods. Boston: PWS-Kent Publishing Company 1988
11 Ben-Tal O, Zivelin A, Seligsohn U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb Haemost 1989; 61: 50-54
12 Gladson CL, Scharrer I, Hach V, Beck KH, Griffin JH. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost 1988; 59: 18-22
13 Pabinger I, Brucker S, Kyrle PA, Schneider B, Kominger HC, Niessner H, Lechner K. Hereditary deficiency of antithrombin III, protein C and protein S: prevalence in patients with a history of venous thrombosis and criteria for rational patient screening. Blood Coagul Fibrinolysis 1992; 3: 547-553
14 Vikydal R, Kominger C, Kyrle PA, Niessner H, Pabinger I, Thaler E, Lechner K. The prevalence of hereditary antithrombin-III deficiency in patients with a history of venous thromboembolism. Thromb Haemost 1985; 54: 744-745
15 Miletich J, Sherman L, Broze Jr G. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317: 991-996
16 Frezzato M, Tosetto A, Rodeghiero F. Validation of a questionnaire for the diagnosis of previous venous thromboembolism. Br J Haematol 1994; 87 (Suppl. 01) 79
17 Rose GA. The diagnosis of ischemic heart pain and intermittent claudication in field surveys. Bull WHO 1962; 27: 645-658
18 The ARIC Investigators. The Atherosclerosis Risk In Communities (ARIC) study: design and objectives. Am J Epidemiol 1989; 129: 687-702
19 Rossi E, Mondonico P, Lombardi A, Preda L. Method for the determination of functional (clottable) fibrinogen by the new family of ACL coagulometers. Thromb Res 1988; 52: 453-468
20 Palareti G, Maccaferri M, Manotti C, Tripodi A, Chantarangkul V, Rodeghiero F, Ruggeri M, Mannucci PM. on behalf of C.I.S.M.E.L. Fibrinogen assays: a collaborative study of six different methods. Clin Chem 1991; 37: 714-719
21 Teien AN, Abildgaard U, Hook M. The anticoagulant effect of heparan sulfate and dermatan sulfate. Thromb Res 1976; 8: 859-867
22 Walker PA, Bauer KA, McDonagh J. A simple, automated functional assay for protein C. Am J Clin Pathol 1989; 92: 210-213
23 Abildgaard U, Lie M, Odegard OR. Antithrombin (heparin cofactor) assay with new chromogenic substrate (S2238 and Chromozyn TH). Thromb Res 1977; 11: 549-553
24 Vinazzer H, Stocker K. Heparin cofactor II: experimental approach to a new assay and clinical results. Thromb Res 1991; 61: 235-241
25 Friberger P, Knos M, Gustavsson S, Aurell L, Claeson G. Methods for the determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis 1978; 7: 138-145
26 Finney DJ. Statistical methods in biologic assay. London: C. Griffin: 1978
27 Tosetto A, Gatto E, Masiero MT, Rodeghiero F. Parallel line bioassay or singlepoint calibration for the establishment of reference ranges. Thromb Res 1994; 75: 479-483
28 Tosetto A, Rodeghiero F. Parallel line bioassay in coagulation laboratory. A program for personal computer use and an example application to ristocetin cofactor assay. Clin Lab Haematol 1991; 13: 371-377
29 Hubbard AR. Standardization of protein C in plasma: establishment of an international standard. Thromb Haemost 1988; 59: 464-467
30 Siedel J, Hagele EO, Ziegerhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983; 29: 1075-1080
31 Abell LL, Levy BB, Brodie BB, Kendall FE. A simplified method for estimation of total cholesterol in serum and demonstration of its specificity. J Biol Chem 1952; 195: 357-366
32 Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982; 28: 1379-1388
33 Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982; 28: 2077-2080
34 Conlan MG, Folsom AR, Finch A, Davis CE, Marcucci G, Sorlie P, Wu KK. Antithrombin III: association with age, race, sex and cardiovascular risk factors. Thromb Haemost 1994; 72: 551-556
35 Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Wu KK. Correlation of plasma protein C levels with cardiovascular risk factors in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) study. Thromb Haemost 1993; 70: 762-767
36 Daniel WW. Biostatistics: a foundation for analysis in the health sciences. New York: J. Wiley & Sons: 1987
37 Solberg HE. Approved recommendation (1987) on the theory of reference values. Part 5. Determination of reference limits. J Clin Chem Clin Biochem 1987; 25: 645-656
38 Reed AH, Henry RJ, Mason WB. Influence of statistical method used on the resulting estimate of normal range. Clin Chem 1971; 17: 275-284
39 Norusis MJ. SPSS/PC+ Statistics 4.0. Chicago: SPSS, Inc. 1990
40 Solberg HE. Establishment and use of reference values. In: Fundamentals of Clinical Chemistry Tietz NW. ed. W. B. Saunders Co.,; Philadelphia: 1987: 197-212
41 Miller GJ, Walter SJ, Stirling Y, Thompson SG, Esnouf MP, Meade TW. Assay of factor VII activity by two techniques: evidence for increased conversion of VII to alpha Vila in hyperlipidaemia, with possible implications for ischaemic heart disease. Br J Haematol 1985; 59: 249-258
42 Tait RC, Walker ID, Islam SIAM, Mitchell R, Conkie JA, McCall F, Davidson JF. Age related changes in protein C activity in healthy adult males. Thromb Haemost 1991; 65: 326-327
43 Mackie IJ, Segal H, Burren T, Gallimore M, Walsh KJ, Robinson G, Machin SJ. Heparin cofactor II levels are increased by the use of combined oral contraceptives. Blood Coagul Fibrinolysis 1990; 1: 647-651
44 Massouh M, Jatoi A, Gordon EM, Ratnoff OD. Heparin cofactor II activity in plasma during pregnancy and oral contraceptive use. J Lab Clin Med 1989; 114: 697-699
45 Andersson TR, Larsen ML, Handeland GF, Abildgaard U. Heparin cofactor II activity in plasma: application of an automated assay method to the study of a normal adult population. Scand J Haematol 1986; 36: 96-102